Apollomics Class A Stock Fundamentals
| APLM Stock | 8.90 0.74 9.07% |
Apollomics Class A fundamentals help investors to digest information that contributes to Apollomics' financial success or failures. It also enables traders to predict the movement of Apollomics Stock. The fundamental analysis module provides a way to measure Apollomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Apollomics stock.
At this time, Apollomics' Net Interest Income is very stable compared to the past year. As of the 1st of December 2024, Depreciation And Amortization is likely to grow to about 758.7 K, while Interest Expense is likely to drop about 109.5 K. Apollomics | Select Account or Indicator |
Apollomics Class A Company Shares Outstanding Analysis
Apollomics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Apollomics Shares Outstanding | 110.27 M |
Most of Apollomics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apollomics Class A is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Apollomics Shares Outstanding Historical Pattern
Today, most investors in Apollomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Apollomics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Apollomics shares outstanding as a starting point in their analysis.
Apollomics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Apollomics Class A has 110.27 M of shares currently outstending. This is 38.92% lower than that of the Biotechnology sector and 3.19% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 80.72% higher than that of the company.
Apollomics Class A Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Apollomics's current stock value. Our valuation model uses many indicators to compare Apollomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Apollomics competition to find correlations between indicators driving Apollomics's intrinsic value. More Info.Apollomics Class A is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Apollomics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Apollomics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Apollomics Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apollomics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apollomics could also be used in its relative valuation, which is a method of valuing Apollomics by comparing valuation metrics of similar companies.Apollomics is currently under evaluation in shares outstanding category among its peers.
Apollomics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apollomics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apollomics' managers, analysts, and investors.Environmental | Governance | Social |
Apollomics Fundamentals
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.63 | ||||
| Operating Margin | (14.32) % | ||||
| Current Valuation | (11.39 M) | ||||
| Shares Outstanding | 110.27 M | ||||
| Shares Owned By Insiders | 47.32 % | ||||
| Shares Owned By Institutions | 2.08 % | ||||
| Number Of Shares Shorted | 289.11 K | ||||
| Price To Book | 0.47 X | ||||
| Price To Sales | 4.67 X | ||||
| Revenue | 821 K | ||||
| EBITDA | (171.75 M) | ||||
| Net Income | (172.59 M) | ||||
| Total Debt | 4.66 M | ||||
| Book Value Per Share | 0.19 X | ||||
| Cash Flow From Operations | (43.21 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 45 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 16.52 M | ||||
| Total Asset | 55.39 M | ||||
| Retained Earnings | (646.97 M) | ||||
| Working Capital | 26.37 M | ||||
| Net Asset | 55.39 M |
About Apollomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apollomics Class A's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apollomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apollomics Class A based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 821 K | 596.8 K | |
| Cost Of Revenue | 694 K | 758.7 K | |
| Stock Based Compensation To Revenue | 15.45 | 7.73 | |
| Sales General And Administrative To Revenue | 25.14 | 23.88 | |
| Research And Ddevelopement To Revenue | 41.65 | 44.94 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (66.79) | (70.13) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Apollomics Piotroski F Score and Apollomics Altman Z Score analysis. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.023 | Quarterly Revenue Growth 2.623 | Return On Assets (0.63) | Return On Equity (1.49) |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.